CompletedPhase 3NCT00168025

Efficacy and Safety of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)

Studying Agammaglobulinemia

Last synced from ClinicalTrials.gov May 3, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: CSL Behring
Principal Investigator: Program Director
CSL Behring
Intervention: Immunoglobulins Intravenous (Human)(drug)
Enrollment: 89 enrolled
Eligibility: 3-70 years · All sexes
Timeline: 2004 – 2006

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00168025 on ClinicalTrials.gov

Other trials for Agammaglobulinemia

Additional recruiting or active studies for the same condition.

RECRUITINGPHASE3NCT06954441
V-IMMUNE: A Novel Immunoglobulin Therapy for Immunodeficiency
On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA.

See all trials for Agammaglobulinemia →

← Back to all trials